

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number	10528974
Filing Date	2005-03-23
First Named Inventor	Paul Murray
Art Unit	<del>1614</del>
Examiner Name	<del>Not yet assigned</del>
Attorney Docket Number	100835-1P US

## **U.S. PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/GS/	1	20040142938		2004-07-22	Sher et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/GS/ ↓	1	03/072570	WO	A1	2003-09-04	Pfizer Products Inc.		<input type="checkbox"/>
	2	1 340 500	EP	A1	2003-09-03	Pfizer Products Inc.		<input type="checkbox"/>
	3	2004/092158	WO	A1	2004-10-28	Pfizer Products Inc.		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10528974	
	Filing Date		2005-03-23	
	First Named Inventor	Paul Murray		
	Art Unit	1614		
	Examiner Name	Not yet assigned		
	Attorney Docket Number	100835-1P US		

/GS/	4	2004196702	JP	A	2004-07-15	Yamanouchi Pharmaceutical Co., Ltd.	<input checked="" type="checkbox"/>
	5	01/32622	WO	A1	2001-05-10	AstraZeneca AB	<input type="checkbox"/>
	6	2004/031193	WO	A1	2004-04-15	AstraZeneca AB	<input type="checkbox"/>
	7	2005/013981	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
	8	2005/013975	WO	A1	2005-02-17	AstraZeneca AB	<input type="checkbox"/>
	9	2005/020986	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>
	10	2005/020985	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>
	11	2005/019172	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
	12	2005/018637	WO	A1	2005-03-03	AstraZeneca AB	<input type="checkbox"/>
	13	2005/020987	WO	A1	2005-03-10	AstraZeneca AB	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

**NON-PATENT LITERATURE DOCUMENTS**

Remove

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10528974
	Filing Date		2005-03-23
	First Named Inventor	Paul Murray	
	Art Unit	1614	
	Examiner Name	Not yet assigned	
	Attorney Docket Number	100835-1P US	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
/GS/	1	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 1470-P, A340 (2003)	<input type="checkbox"/>
	2	Turnbull, A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 1485-P, A343 (2003)	<input type="checkbox"/>
	3	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium (Sept 2003)	<input type="checkbox"/>
	4	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002)	<input type="checkbox"/>
	5	Vertigan, H. et al. "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich (2004)	<input type="checkbox"/>
	6	Bartlett, J. et al. "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego (2005)	<input type="checkbox"/>
	7	Simpson, I. et al. "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, (Sept 2005). Poster EOM	<input type="checkbox"/>
	8	Green, A R. et al. "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 279(45), 46474-46482 (2004)	<input type="checkbox"/>
	9	Roberts, P A. et al. " The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology-London 545(1), 297-304 (2002)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button. Add

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number	10528974
	Filing Date	2005-03-23
	First Named Inventor	Paul Murray
	Art Unit	1614
	Examiner Name	Not yet assigned
	Attorney Docket Number	100835-1P US

EXAMINER SIGNATURE			
Examiner Signature	/Golam Shameem/	Date Considered	10/31/2007
<p><b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			
<p><small><sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="http://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.</small></p>			


PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned <b>10/528974</b>
				Filing Date	March 23, 2005
				First Named Inventor	Paul Murray
				Art Unit	<u>Not Yet Assigned</u>
				Examiner Name	<u>Not Yet Assigned</u>
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-835

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/GS/	BA	WO-01/28993 A	04-26-2001			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>3</sup>
/GS/	CA	PCT/GB2003/004217 Search Report 6/8/2004				
	CB	Meth-Cohn et al., "The preparation and formylation of 2-acetamidothiophenes," Synthesis 2:133-135 (1980)				
	CC	Nakamura, "Construction of heterocyclic compounds by use of alpha-diazaphosphonates: new one-pot syntheses of indoles and isocoumarines," Organic Letters 4(14)2317-2320 (2002)				
	CD	Shvedov et al., "'2-Aminothieno '2,3-bipyridine derivatives," Database CA 'Online' Chemical Abstracts Service Database accession no. 78:159580 XP002266826 (1972)				
	CE	Sugiyama et al., "Condensed thienopyrimidines. IV. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidine derivatives," Chemical & Pharmaceutical Bulletin 37(10):2171-2722 (1989)				
	CF	Sugiyama et al., "Condensed thienopyrimidines. 5. Studies on the thermal cyclization of various ortho-formylthiophenecarbamates with ethanolamine," Heterocycles 29(7):1317-1323 (1989)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Golam Shameem/	Date Considered	10/31/2007
-----------------------	-----------------	--------------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/528974
				Filing Date	March 23, 2005
				First Named Inventor	Paul Murray
				Art Unit	<del>1614</del>
				Examiner Name	<del>Not Yet Assigned</del>
Sheet	1	of	3	Attorney Docket Number	ASZD-P01-835


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/GS/	AA*	US-2004/0048878-A1	03-11-2004	Cai et al.	
/GS/	AB*	US-2004/0220229-A1	11-04-2004	Bussolotti et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
/GS/	BA	EP	1088824 A2	04-04-2001		
	BB	EP	1136071 A3	03-26-2003		
	BC	WO	1994/18196 A1	08-18-1994		
	BD	WO	2001/28993 A2	04-26-2001		
	BE	WO	2002/06246 A1	01-24-2002		
	BF	WO	2002/20530 A1	03-14-2002		
	BG	WO	2003/074484 A1	09-12-2003		
	BH	WO	2003/074485 A2	09-12-2003		
	BI	WO	2003/074513 A2	09-12-2003		
	BJ	WO	2003/074517 A1	09-12-2003		
	BK	WO	2003/074531 A1	09-12-2003		
	BL	WO	2003/074532 A1	09-12-2003		
	BM	WO	2003/091213 A1	11-06-2003		
	BN	WO	2004/041780 A2	05-21-2004		
	BO	WO	2004/058715 A1	07-15-2004		Abstract only
	BP	WO	2004/113345 A1	12-29-2004		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/GS/	CA	Adams et al., "4-Amino-4,5-dihydrothiophene-2-carboxylic acid," J. Org. Chem. 50:2730-2736 (1985)		
	CB	Binder et al., "Eine einfache herstellungsmethode fur 2-aminothiophene," Synthesis Communications 4:255-256 (1977)		
	CC	Binder et al., "Thiopen als strukturelement physiologisch aktiver substanzen, 8. mitt. 1H5H-imidazo[1,2-a]thieno[3,4-d]pyrimidin-2(3H-one," Arch Pharm. 314:556-564 (1981)		
	CD	Bjork et al., "Improved syntheses of thieno[2,3-b]- and [3,2-b]-fused naphthyridines," J. Heterocyclic Chem. 32:751-754 (1995)		

Examiner Signature	Date Considered
-----------------------	--------------------



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/528974
				Filing Date	March 23, 2005
				First Named Inventor	Paul Murray
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-835

/GS/	CE	Boger et al., "Total synthesis of distamycin A and 2640 analogues: A solution-phase combinatorial approach to the discovery of new, bioactive DNA binding agents and development of a rapid, high-throughput screen for determining relative DNA binding affinity or DNA binding sequence selectivity," J. Am. Chem. Soc. 122:6382-6394 (2000)
	CF	Brugier et al., "α-Substitution of β-thienylcarbamates: alkylation, vinylation and Pd-catalyzed coupling reactions," Tetrahedron 56:2985-2993 (2000)
	CG	Brugier et al., "Studies on the reactivity of N-(3-thienyl)carbamates," J. Chem. Soc., Perkin Trans. 1:37-43 (2001)
	CH	Brugier et al., "Synthesis and reactivity of alkyl (4-aminothien-3-yl)carbamates," Tetrahedron 53(30):10331-10344 (1997)
	CI	Brunnett et al., "Heterocyclic amines. IV. Urethan and urea derivatives of 3-aminothiophene (1)," J. Heterocyclic Chem. 5(3):417-418 (1968)
	CJ	Carroll et al., "Competitive ortho metalation effects: the kinetic and thermodynamic lithiation of 3-(tert-Butoxycarbonyl)amino-4-caromethoxythiophene," Tetrahedron Letters 38(15):2637-2640 (1997)
	CK	Eras et al., "Reactivity of theinopyrroles. synthesis of isomeric nitro and bromothiopyrroles," J. Heterocyclic Chem. 21:215-217 (1984)
	CL	Galvez et al., "Synthesis of isomeric β-haloethylthienopyrroles," J. heterocyclic Chem., 21, 393-395 (1984)
	CM	Galvez et al., "Synthesis of thiophenedicarbonyldiazides and Di-t-butyl thiophenedicarbamates," J. Heterocyclic Chem. 23:1103-1108 (1986)
	CN	Jones et al., "The vilsmeier reaction of fully conjugated carbocycles and heterocycles," Organic Reactions 49:1-39 (1997)
	CO	Kobayashi et al., "Heterocyclic sulfonyl compounds and activated blood coagulation factor X (FXa) inhibitors containing them," Chemical Abstracts XP002267904 & JP 2001 294572 (2001)
	CP	Linda et al., "The mechanism of the Vilsmeier-Haack reaction. Part III. Structural and solvent effects," J. Chem. Soc. Perkins Trans II, 1610-1612 (1974)
	CQ	Marques et al., "Toward an understanding of the chemical etiology for DNA minor-groove recognition by polyamides," Helvetica Chimica acta 85:4485-4517 (2002)
	CR	Martin et al., "Nuclear magnetic resonance investigations of carbonium ion intermediates. Part II. Exchange reactions in chloro-iminium salts (Vilsmeier-Haack reagents)," Journal Chem. Soc., Perkins Trans II 642-646 (1974)
	CS	Martin et al., "Recherches sur la reaction de vilsmeier-haack etude du mecanisme de formation du complexe par des mesures cinetiques en resonance magnetique nucleaire," Tetrahedron Letters 58:5061-5064 (1970)
	CT	Meth-Cohn et al., "A versatile new synthesis of quinolines and related fused pyridines. Part II," Tetrahedron Letters 33:3111-3114 (1979)
	CU	Meth-Cohn et al., "A versatile new synthesis of quinolines and related fused pyridines. Part 7. The conversion of acetamidothiophenes into thienopyridines," Journal Chem. Soc., Perkins Trans. I 1531-1536 (1981)
	CV	Meth-Cohn et al., "A versatile new synthesis of quinolines, thienopyridines and related fused pyridines," Tetrahedron Letters 23:2045-2048 (1978)
	CW	Meth-Cohn et al., "The preparation and formylation of 2-acetamidothiophenes," Synthesis 2:133-135 (1980)
✓	CX	Nakamura, "Construction of heterocyclic compounds by use of alpha-diazaphosphonates: new one-pot syntheses of indoles and isocoumarines," Organic Letters 4(14):2317-2320 (2002)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
				Application Number	10/528974
				Filing Date	March 23, 2005
				First Named Inventor	Paul Murray
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	ASZD-P01-835


/GS/	CY	Rajanna et al., "Kinetics and mechanism of Vilemeier-Haack synthesis of 3-formyl chromones derived from o-hydroxy aryl alkyl ketones: A structure reactivity study," Tetrahedron 52(10):3669-3682 (1996)	
	CZ	Seela et al., "168. Synthesis of 2'-deoxyribofuranosides of 8-Aza-7-deazaguanine and related pyrazolo[3,4-d]pyrimidines," Helvetica Chimica Acta 69:1602-1613 (1986)	
	CA1	Shinkwin et al., "Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and Thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP)," Bioorganic & Medicinal Chemistry 7:297-308 (1999)	
	CB1	Shvedov et al., "2-Aminothieno[2,3-b]pyridine derivatives, Chemical Abstracts, XP002266826 & SU364613 (1973)	
	CC1	Soth et al., "Recherches en serie heterocyclique. XXIX. Sur des voies d'accès à des thieno, selenolo, furo et pyrrolopyrroles," Canadian Journal of Chemistry 56(6):1429-1434 (1978)	
	CD1	Stanetty et al., "Herbizide thienylharnstoffe, I," Monatshefte für Chemie 120:53-63 (1989)	
	CE1	Sugiyama et al., "Condensed thienopyrimidines. IV. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidine derivatives," Chemical & Pharmaceutical Bulletin 37(10):2171-2722 (1989)	
	CF1	Sugiyama et al., "Condensed thienopyrimidines. 5. Studies on the thermal cyclization of various ortho-formylthiophenecarbamates with ethanolamine," Heterocycles 29(7):1317-1323 (1989)	
✓	CG1	Szabo et al., "Experimental and theoretical study of orientation in the nitration of dithieno[3,4-b:3',4'-d]pyridine," J. Organic Chem 56:1590-1596 (1991)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Golam Shameem/	Date Considered	10/31/2007
--------------------	-----------------	-----------------	------------





PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/528974
				Filing Date	March 23, 2005
				First Named Inventor	Paul Murray
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-835

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/GS/	BQ		SU-364613	12-28-1972	S. Ordzhonikidze All-Union Pharmaceutical Chemistry Research Institute		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Golam Shameem/	Date Considered	10/31/2007
-----------------------	-----------------	--------------------	------------